Prof. Daniel Scherman is a leading expert in bioenergetics, neuropharmacology, gene therapy, and bioimaging, with a distinguished career spanning fundamental research and translational innovation. His work has contributed to the development of novel bio-imaging agents and the understanding of the natural history of early Parkinson’s disease. He is internationally recognised for pioneering contributions in gene therapy and genetic vaccination, including the development of physical gene delivery methods, and the concepts of biosafe mini-plasmids and minicircles.

Prof. Scherman founded the Paris Centre of Pharmaceutical Research at the Paris Faculty of Pharmacy and the Laboratory of Chemical and Biological Tools for Health (UTCBS). He has served as Committee President of the European Society of Cell and Gene Therapy, and as President of the Pharmacology and Bioimaging Section at the French National Center for Scientific Research (CNRS). He was also Scientific Director of the Genethon Laboratory (Telethon/AFM – French Myopathy Association), and acts as an expert for Horizon 2020 European Committees.

He has authored over 590 peer-reviewed articles and 50 book chapters, accumulating an H-index of 64 and over 18,000 citations, reflecting the impact of his research across biotechnology and medicine.

Prof. Daniel Scherman has served as Officer of the Medicine and Life Sciences Division since March 2017, across three consecutive mandates: March 2017 – February 2020; March 2020 – February 2023, extended until April 2024 due to the COVID-19 pandemic; May 2025 – April 2028 (current and final consecutive term, in accordance with the EurASc Bylaws).

Also Member of the Executive Committee of EurASc, appointed by decision of the General Board on June 2023, following the resignation of Prof. Paul Tréguer.